Hilary Eaton

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.